| | You could be unknowingly consuming up to 5x more gluten than what is safe.
The diet is not enough.
You deserve better treatments.
You deserve a cure.
Together, we can make that a reality.
Come learn how at the National Conference.
Your health and quality of life depend on it. | | This is your opportunity to hear about the cutting-edge
advancements in drug development for celiac disease directly from our
world-renowned panel of biopharmaceutical industry leaders! | | | | | | | | Nexvax2® What if you never had to worry about accidental gluten consumption again? Bob Anderson, Chief Scientific Officer of ImmusanT, is pioneering the development of a vaccine to protect celiac disease patients against the damaging effects of accidental gluten exposure. Nexvax2®, now entering Phase 2 clinical trials, ultimately aims to restore immune tolerance in patients with celiac disease. | | | | IMGX-003 More than 60% of celiac disease patients continue to suffer from symptoms while attempting to follow the gluten-free diet. The majority of patients in clinical remission still present with abnormalities in their small intestinal biopsies. In response to the clear need for non-dietary treatment options, Jack A. Syage, CEO of ImmunogenX, leads the development of IMGX-003: a celiac disease treatment shown in clinical trials to reduce intestinal injury caused by gluten and improve patients’ symptoms. | | | | Larazotide Acetate Wendy Perrow, MBA, licensed Larazotide Acetate (INN-202) to Innovate Biopharmaceuticals, a drug currently entering phase 3 clinical trials after demonstrating safety and efficacy in more than 800 patients. When celiac disease patients consume gluten, it disrupts the connections between the cells in the outer layer of their intestines, creating openings for large molecules to pass through where there should be none. This process triggers inflammation that damages the intestinal villi. The goal of INN-202 is to close these openings, thereby preventing damaging inflammation in the small bowel. | | | | AMG 714 Sometimes a molecule being evaluated for its efficacy in treating a specific disease can show great potential outside its intended treatment population. One such promising example is anti-IL-15 antibody (AMG 714); first developed and tested by Amgen, the world’s largest independent biotechnology firm, for the treatment of rheumatoid arthritis and psoriasis. Francisco Leon, M.D., former CEO and current Advisor to Celimmune, recognized the antibody’s potential to treat refractory and non-responsive celiac disease. In an exciting deal likely to benefit the celiac disease community, Amgen licensed the molecule to Celimmune to develop, manufacture, and commercialize AMG 714 on a worldwide basis with exclusive rights to reacquire the drug at a later stage. AMG 714 is currently amid phase 2 clinical trials. | | | | | | | | | Celiac Disease Foundation
20350 Ventura Boulevard, Suite 240
Woodland Hills, California 91364
818.716.1513
info@celiac.org | |  | | | | | | |
